Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lithium plus quetiapine versus lithium alone or quetiapine alone for bipolar disorder
ISRCTN17178652Phase 3Recruiting
- Sponsor
- University of Birmingham
- Start
- Nov 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial in bipolar disorder (BD) comparing Lithium + quetiapine, Lithium monotherapy and Quetiapine monotherapy (3 arms). Primary endpoint: Time to first new mood episode. Started Nov 2025; status: recruiting.
02
Drugs
lithiumquetiapine
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on ISRCTN17178652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN17178652.